Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

CTVA · Q1 2026 Earnings

Corteva

Reported May 5, 2026

30-second summary

Corteva delivered Q1 FY2026 revenue of $4.91B (+11.1% YoY), beating consensus of $4.64B by 5.8%, on 7% organic growth (Seed organic +9%, CP organic +4%; reported Seed +11.7%, reported CP +10.1%). Management reaffirmed FY2026 guidance: operating EPS of $3.45–$3.70, operating EBITDA of $4.0–$4.2B, and EBITDA margins of 22–23%. The headline of the print is operational: Q1 EBITDA up 21% YoY with +240bps of margin expansion, CP returning to double-digit reported growth, and management pulling the royalty-positive crossing into 2026 — described on the call as "new information for this morning."

Headline numbers

EPS

Q1 FY2026

$1.50

-27.1% vs est.

Revenue

Q1 FY2026

$4.91B

+11.1% YoY

+5.8% vs est.

Gross margin

Q1 FY2026

51.6%

Free cash flow

Q1 FY2026

$-2.97B

Operating margin

Q1 FY2026

17.5%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$4.91B	+11.1%	$3.91B	+25.4%
EPS	$1.50	—	$0.22	+581.8%
Gross margin	51.6%	—	42.4%	+920bps
Operating margin	17.5%	—	-13.5%	+3100bps
Free cash flow	$-2.97B	—	—	—

Guidance

FY2026 full-year guidance significantly raised (EPS +2.9-7.7%, EBITDA +5.3-7.9%) following strong Q1 results, but FY2026 free cash flow guidance withdrawn.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q1 FY2026	—	$4.905 billion	+$0.265B above consensus estimate (+5.8%)	Beat
Operating EPS	Q1 FY2026	—	$1.50	-$0.32 below consensus estimate (-27.1%)	Missed
Operating EBITDA	Q1 FY2026	—	$1,438M	In-line with quarterly run-rate implied by FY guidance	Met

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Operating EPS	FY2026	$3.25 to $3.45	$3.45 to $3.70	+$0.20 to $0.25 at range midpoints (+2.9% to +7.7%)	Raised
Operating EBITDA	FY2026	$3.8 billion to $3.9 billion	$4.0 billion to $4.2 billion	+$0.2 billion to $0.3 billion at range midpoints (+5.3% to +7.9%)	Raised
Operating EBITDA Margin	FY2026	approximately 165 basis points expansion	22% to 23%	Margin guidance now stated as absolute range; prior guidance focused on expansion vs FY2025	Raised
Free Cash Flow	FY2026	approximately $1.9 billion	Withdrawn — no replacement	—	Withdrawn

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Seed	$3.023B	+11.7%
Crop Protection	$1.882B	+10.1%
Corn Seed	$2.373B	+14.7%
Seed Segment EBITDA	$1,034M	—
Crop Protection Segment EBITDA	$434M	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
North America	$2.439B	+10.0%
EMEA	$1.655B	+11.6%
Latin America	$0.506B	+13.5%
Asia Pacific	$0.305B	+5.5%
Rest of World	$2.466B	+11.6%
Operating EBITDA	$1,438M	—
Operating EBITDA Margin	29.3%	—
Organic Sales Growth	7.0%	—
Price & Product Mix Impact	+1% contribution to organic growth	—
Volume Impact	+6% contribution to organic growth	—
Base Income Tax Rate	16.4%	—

Management tone

Q2 cost-program acceleration → Q3 controllable-benefits reframe and FY26 pre-announce → Q4 Bayer FTO unlock and royalty pull-forward → Q1 reaffirmation with H1 outperformance and royalty-positive pull-in.

Crop Protection has flipped from "modest growth" thesis to confirmed double-digit reported Q1 print. In Q3 2025 management called for "low single digit growth" in the 2026 CP industry — the first such call in years. Q4 reaffirmed "modest growth." This quarter, CP delivered +10.1% YoY reported (+4% organic) on price/mix −2%, with volume +6% and currency +6% carrying the print. The cyclical bottom-of-cycle call from Q3 is now anchored in actuals on a volume basis — and management's "the first half is playing out a little better than expected" framing is the cautious uplift version of an explicit upgrade they likely don't want to make on a Q1 call. CP pricing remains a watch item: management reiterated low single digit pricing headwinds for FY2026 CP.

Royalty positive crossing into 2026 is "new information." The Q4 narrative was royalty neutrality in 2026, pulled forward two years from August's 2028 target and four years from the original 2030. This quarter Chuck Magro stated: "Crossing the milestone of royalty neutrality into royalty positive later this year is a monumental accomplishment… this is the first year that we're going to be royalty positive. And that's new information for this morning." The trajectory keeps accelerating. The seed P&L drag that defined post-DowDuPont separation isn't just gone — it's now structurally additive, with another $30M decrease in net royalty expense recorded in Q1.

Vylor positioning as a "classic growth compounder" reframes the seed spinco. Prior quarters discussed the post-separation Seed entity in generic terms. This quarter's framing — "margins, conversion to free cash flow, and top and bottom line growth" — explicitly maps to a growth-compounder valuation framework rather than a cyclical-ag-inputs frame. With separation targeted for Q4 2026 and Investor Day on September 15th, this is the start of management setting the post-separation multiple. Luke Kissam named CEO of new Corteva (CP), joining June 1.

Separation dis-synergies trending favorably. Q4 disclosed ~$100M of net dis-synergies with $50M in the 2026 guide. This quarter management called the actual trajectory "favorable" against the $100M estimate. Combined with tariffs now "slightly favorable" versus February expectations and a Middle East oil price headwind of $40M, the net of macro line items is moving Corteva's way. One-time separation costs sized at ~$350M with majority in H2.

Capital structure signal: $1.5B discretionary pension contribution. Board-approved last week as part of standalone capital structure setup, intended to position both companies for investment-grade credit profiles. ~$290M of tax savings on the contribution. This is a real use of FY2026 cash that wasn't in the February framing — and partially explains why management is leaning on operational FCF conversion language ("in line with our midterm target") rather than reaffirming a specific dollar FCF number this quarter.

Recurring themes management leaned on this quarter:

Royalty positive transition and licensing scaleVylor positioning as high-margin growth compounderCP market inflection after three years of declineSeparation execution on track with favorable disenergiesPremium technology demand supporting price mix gainsBiofuels tailwind creating structural agricultural shifts

Risks management surfaced:

Middle East conflict impact on oil prices ($40M headwind identified)Farmer margin compression from input cost inflationBrazil safrinha acreage pressure from fertilizer/energy costsCompetitive threats from new soybean technology entrantsTariff and supply chain uncertainties persisting

Answers to last quarter's watch list

FY2026 productivity delivery net of tariffs. Management characterized tariffs as "slightly favorable" versus the February headwind framing, and Q1 EBITDA of $1.438B at 29.3% margin (+240bps YoY) suggests productivity is on track. Seed and CP combined delivered ~$70M in productivity and input cost benefits in Q1. Status: Resolved positively

H1 phasing delivery. Q1 EBITDA of $1.438B is ~35% of the $4.1B FY midpoint. Combined with the cautious uplift that "the first half is playing out a little better than expected," the phasing is holding. Status: Resolved positively

Bayer settlement P&L mechanics in Q1. Royalty trajectory is accelerating beyond Q4 disclosure — management now flags royalty-positive crossing in 2026 versus the Q4 framing of neutral, with another $30M reduction in net royalty expense in Q1. The Bayer agreement cash impact hit Q1 free cash flow as expected. Status: Resolved positively (on P&L), Continue monitoring (on cash flow mechanics)

Separation milestones at September Investor Day. Investor Day confirmed for September 15th. Dis-synergy tracking favorable vs $100M estimate, with $50M in the 2026 guide. Vylor (SpinCo Seed) explicitly positioned as a growth compounder for the first time. New CEO and ELTs announced; Form 10 filed with public filing expected end of Q2. Status: Continue monitoring

Crop Protection fungicides recovery. Fungicides delivered +10% YoY reported in Q1 ($334M vs $304M), with +2% organic. The −15% Q4 fungicide print appears to have been at or near trough. Status: Resolved positively

FY2026 free cash flow guidance. Management did not restate the FCF dollar target this quarter, but did anchor on midterm conversion (~45% midpoint of 40–50%) absent the Bayer agreement, separation costs, and the newly disclosed $1.5B pension contribution. The reported number will reflect these discrete uses. Status: Continue monitoring

What to watch into next quarter

EBITDA raise alongside the next print. Management explicitly said they prefer to update guidance after the North American season completes in Q2. With H1 trending ahead of expectations, favorable tax rate (16.4% Q1 vs. ~21% guide), favorable currency, and favorable tariffs, the setup for a Q2 raise is in place — watch for whether EPS, EBITDA, or both move.

FCF dollar disclosure. With the $1.5B pension contribution, ~$350M separation costs, and the Bayer agreement cash impact all hitting FY2026, watch Q2 for an explicit reported FCF dollar range alongside the midterm-conversion framing.

Crop Protection price/mix sustainability. Q1 organic growth was +6% volume and +1% price/mix at the company level, but CP-specific price was −2%. Management guided FY2026 CP as low single digit pricing headwinds. Watch whether Q2 confirms the H2 framework of low-single-digit CP price declines holding rather than worsening.

Latin America Safrinha and second-half setup. Management flagged higher energy prices as a potential drag on Brazilian acreage decisions for the second corn crop, with $40M Middle East/oil headwind already in the guide. Watch Q2 for Safrinha area confirmation and whether the back-half biologicals ramp materializes.

Separation milestones at September 15 Investor Day. Standalone segment financials for Vylor (Seed) and new Corteva (CP), multi-year financial plans, headquarter locations, board composition, and final capital structure will set the post-spin valuation anchors.

China CP supply dynamics. Management flagged early signs of slowing Chinese AI exports into Brazil and ~8% price increases on certain AIs from China VAT changes. Minimal 2026 impact expected but could become a tailwind into late-2026/H1-2027 — worth tracking for the next CP cycle inflection.

Sources

Corteva Q1 FY2026 Earnings Schedules, SEC Form 8-K: https://www.sec.gov/Archives/edgar/data/1755672/000175567226000008/a3312026enrschedules.htm
Tapebrief Q4 FY2025 CTVA brief — FY2025 prior guide baseline and watch list.
Tapebrief Q3 FY2025 CTVA brief — controllable-benefits framing and CP industry growth call.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.